Aldeyra Therapeutics, Inc. (ALDX) Stock

Aldeyra Therapeutics, Inc. (ALDX) is a Healthcare stock trading at $1.52 (as of 2026-08-21), with a market capitalization of $91.69M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Aldeyra Therapeutics, Inc. is a biotechnology company developing and commercializing medicines targeting immune-mediated ocular and systemic diseases. Its pipeline includes RASP modulators such as reproxalap and ADX-629 in late- and mid-stage clinical development for conditions including dry eye disease, allergic conjunctivitis, psoriasis, asthma and COVID-19, as well as ADX-2191, a dihydrofolate reductase inhibitor, and other programs under development through collaborations.

Understand Aldeyra Therapeutics, Inc.: how it makes money

Aldeyra Therapeutics develops and commercializes medicines for immune-mediated ocular and systemic diseases, aiming to generate revenue from the successful development and approval of its pipeline candidates.

Its profit model is driven by clinical-stage validation (Phase III, Phase II, and Phase 3) that can lead to approvals and commercialization, since reported revenue is $0.0B for the latest period.

Business quality (Weak): Clinical execution risk is central, and investors should focus on late-stage readouts for the lead candidate, while acknowledging the company is not yet generating revenue.

Bull case

  • Late-stage pipeline for ocular disease: Reproxalap (a reactive aldehyde species, RASP, modulator) is in Phase III for dry eye diseases and allergic conjunctivitis.
  • Demonstrated clinical trial scale and safety exposure: The company reports 116 patients enrolled in the Phase Three Dry Eye Chamber Trial, and a safety database including 1,200 patients administered reproxilab across 14 clinical trials.

Bear case

  • No reported revenue yet: For the period ended 2026-03-31, revenue is reported as $0.0B, indicating dependence on future commercialization rather than current product sales.
  • Material operating losses: Reported operating margin_pct is -630.0 for the period ended 2026-03-31, reflecting ongoing costs before commercial revenues.
  • Clinical outcomes are still pending: Key candidates are still in clinical phases (Phase III for dry eye, Phase II for multiple indications for ADX-629, and Phase 3 for ADX-2191), so efficacy and regulatory success are not assured.
Valuation — source: SEC EDGAR (first-party)
Price$1.52
Market Cap$91.69M
Price / Book2.42
Price / Sales37.68
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$3.32M
Net Margin-1018.3%
Revenue Growth (YoY)-54.1%
EPS Growth (YoY)-43.8%
Financial Health — source: SEC EDGAR
Altman Z-Score-8.27 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($19.16M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOTodd C. Brady
Employees9
CountryUS
IPO Date2014-05-02

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Biomea Fusion, Inc. (BMEA)
  • Fortress Biotech, Inc. (FBIO)
  • Acrivon Therapeutics, Inc. Common Stock (ACRV)
  • Rallybio Corporation (RLYB)
  • Gain Therapeutics, Inc. (GANX)
  • Adicet Bio, Inc. (ACET)
  • MAIA Biotechnology, Inc. (MAIA)
  • LifeVantage Corporation (LFVN)
ALDX earnings history · ALDX institutional & insider holders · ALDX KPIs & operating metrics · ALDX financials · ALDX investor presentations & press releases · ALDX SEC filings · ALDX peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.